CN1267516A - Adhesive polymer substrate and its application - Google Patents

Adhesive polymer substrate and its application Download PDF

Info

Publication number
CN1267516A
CN1267516A CN 99103062 CN99103062A CN1267516A CN 1267516 A CN1267516 A CN 1267516A CN 99103062 CN99103062 CN 99103062 CN 99103062 A CN99103062 A CN 99103062A CN 1267516 A CN1267516 A CN 1267516A
Authority
CN
China
Prior art keywords
substrate
medicine
addition
deionized water
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 99103062
Other languages
Chinese (zh)
Other versions
CN1149976C (en
Inventor
王英驰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB991030621A priority Critical patent/CN1149976C/en
Publication of CN1267516A publication Critical patent/CN1267516A/en
Application granted granted Critical
Publication of CN1149976C publication Critical patent/CN1149976C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

In the presence of cross linking agent, monomer for polymer, solvent, deionized water, moisture maintaining agent, additive and initiator are mixed in certain proportion and the mixture is spread onto lining carrier and polymerized at 25-80 deg.c to obtain adhesive substrate. The present invention has the integral storing layer, adhesive layer and release-controlling layer structure and simplifies the skeleton release-controlling structure technology. The adhesive substrate has the advantages of no toxin, no sensitivity, large medicine carrying amount, being conductive and adhesive, etc. so that it may be used as medicine substrate for transdermal absorption agent and ion introducing agent.

Description

A kind of adhesive polymer substrate and application thereof
The present invention relates to substrate that pharmaceutical preparation uses more particularly, is substrate and the application thereof that a kind of percutaneous drug administration preparation is used.
So-called percutaneous drug administration preparation is meant medicine with the percutaneous skin corium of given pace, absorbs through capillary tube to enter the class preparation that human circulation produces drug effect, comprises ointment and plaster two big classes, narrow sense mainly be meant the plaster that can play the whole body therapeutic effect.Plaster is with medicine dissolution or is mixed in the adhesive matrix that the stand is coated in the exterior-applied formulation that sticks for skin on the back lining materials.
The tradition Western medicine does not have the custom of percutaneous dosing, since the scopolamine percutaneous drug administration preparation of U.S. Aiza company product in 1981 is asked the city, the development of percutaneous drug administration preparation and substrate thereof is very fast, and existing substrate kind mainly contains following four kinds by the structure branch: 1. film--reservoir devices; 2. framework controlled release type; 3. pair micro-reservoirs control release type; The adhesive control release type (" percutaneous dosing system system ", Chinese Medicine science and technology publishing house, P10).
Chinese medicine uses the existing history of more than one thousand years of plaster treatment disease, now still is being extensive use of, be mainly black plaster, rubber plaster etc. (" pharmaceutical necessities complete works ", Sichuan Science Press, P106).Because conventional dosage forms such as black plaster still uses deleterious Plumbum preparatium to boil so far, and the technology controlling and process difficulty, use inconvenient; What use was more at present is the rubber plaster of SHANGSHI ZHITONG GAO one class, because medicine can only place the binding agent of rubber-based, the restriction that is subjected to adhesive coating thickness and keeps viscosity, content of dispersion is little, and easily cause skin allergy, so its scope of application is very limited.
The objective of the invention is to overcome the shortcoming of existing substrate, provide a kind of and have that nontoxic, no sensitization, storage dose are big, preparation technology simply, the surface has the adhesive polymer substrate of certain viscosity.
Another object of the present invention is that adhesive polymer substrate is used for the agent of percutaneous iontophoresis.
Main technical schemes of the present invention: be to carry out homogeneous polymerization after polymeric substrate, solvent, deionized water, wetting agent, additive and initiator are mixed by a certain percentage by simple method and in polymerization process, adopt cross-linking agent to reach the polymer matrix of half cross-linked state.
The used raw material of substrate of the present invention comprises: polymer monomer base material, solvent, remove dried up, wetting agent, additive, cross-linking agent, initiator, its preparation process comprises:
1. polymeric substrate is dissolved in the deionized water, makes substrate solution;
2. adding wetting agent, additive, solvent in the substrate solution in (1) step fully stirs evenly;
3. cross-linking agent is joined in (2) mixed solution in step, obtain treating poly-liquid after stirring evenly;
4. treat to add initiator in the poly-liquid in (3) step, shakeout through pouring into behind the mixing on the backing layer carrier, promptly obtain the substrate that the surface has autohension at 25-80 ℃ of following polymerase 10 .5-30min, cover adherent layer at last, excision forming, stromal thickness reach 50 μ m-3.0mm.
When the polymer monomer base material of described (1) step usefulness is polyvinyl alcohol, adds deionized water earlier it is fully expanded, under 80-95C, make its whole dissolvings then; Described sodium acrylate and acrylamide are polymer monomers, aggregate into sodium polyacrylate and polyacrylamide in the presence of initiator, as using the acrylic acid sodium salt, the sodium hydroxide solution that the available deionized water of elder generation makes joins in the acrylic acid, control degree of neutralization 50-70% makes sodium acrylate.
Described stromal surface viscosity is to be controlled by the addition of cross-linking agent, and stromal surface viscosity of the present invention is 0.3-4.5N/cm (recording by YY0148 medical rubber cream method).
Described polymeric substrate be selected from acrylic acid amides, sodium acrylate, the polyvinyl alcohol any, two or three mixture, form the polymeric solid phase framing structure, its addition is the 4-40% of substrate weight.
Described solvent comprises esters, low mass molecule alcohol class, and its addition is the 4-40% of substrate weight, and it can be stored among the framing structure.
Described wetting agent comprises propylene glycol, glycerol, and its addition is the 12-35% of substrate weight.
Described deionized water is the 12-40% of substrate weight.
Described additive comprises Polyethylene Glycol, gelatin, alginate, hydroxypropyl cellulose, and its addition is the 0-15% of substrate weight, and main effect is the thickening suspending.
Described cross-linking agent is the bisacrylamide class, comprises N-N methylene-bisacrylamide, the two allylamines of methene; The allyl esters comprises dially phthalate, p-phthalic acid, diallyl, diallyl oxalate, maleic acid monoene propyl ester; Halogenation alkylene oxide hydroxyl class comprises that epoxychloropropane and polyepoxy compound comprise Ethylene glycol diglycidyl ether, propylene glycol diglycidylether, glycerin diglycidyl ether, and its addition is the 0.02-0.5% of base material monomer weight.
The hydrogen reduction initiator that described initiator comprises the peroxide initiator of peroxidating benzoic acid and comprises persulfate-sodium sulfite, hydrogen peroxide-L ascorbic acid, its addition is the 0.01-0.1% of base material monomer weight.
Substrate of the present invention can prepare percutaneous drug administration preparation and comprise with Western medicine and make cutaneous permeable agent, make plaster, make pharmaceutical electrode with Chinese medicine with Chinese medicine or Western medicine, concrete preparation method: with medicine dissolution or be blended in the base starting material and obtain through polymerization, perhaps drug solution or suspension are spread upon stromal surface equably, cover adherent layer, leave standstill and made in 48 hours.
In the time of in medicine dissolution or mixed-matrix, become drug solution and transdermal permeation-promoter, surfactant to mix with the raw material of substrate before the polymerization procedure in preparation substrate process together with dissolution with solvents medicine by method commonly used, after polymerization promptly obtains required product.Described transdermal permeation-promoter is a medicine material commonly used, comprise oleic acid, oleyl alcohol, azone, potassium chloride (or sodium chloride), cineole, Mentholum, its addition is drug dose 0.5-20% normally, described medicine comprises the Western medicine and the Chinese medicine of water preparation, tincture, extractum, esters preparation and Chinese medicine extract, described surfactant is ion-type, nonionic, a neutral surfactant commonly used in the medicament, its addition is the 0-20% of drug dose, and surfactant is selected for use according to the requirement of medicine or need not.
Matrix conductivity of the present invention can be near human body skin, thereby can be made into pharmaceutical electrode near human body skin with conductive characteristic, being about to medicine and sodium chloride or potassium chloride sneaks in the substrate, concrete grammar: be in preparation substrate process, to add medicine and potassium chloride or sodium chloride and with base starting material polymerization on the conduction backing, adherent layer, excision forming get final product on the polymerization bonnet.Described medicine should be the medicine that can carry out iontophoresis with conventional method, comprises Chinese medicine or Western medicine.The amount of described potassium chloride or sodium chloride is the 1-5% of the deionized water in the substrate.Described conduction backing comprises conduction-insulating composite materials such as aluminum-plastics commonly used, conductive plastics-non-woven fabrics.
Advantage of the present invention and effect: the present invention is owing to add proper amount of cross-linking agent in treating poly-liquid, make solid polymer form half cross-linked state, liquid phase solvent is wrapped in the solid phase composition, pass through the homogeneous phase polymerisation in bulk then, formation can be maintained fixed shape and surperficial high molecular polymer gel-type drug matrices with certain viscosity; The present invention has the structure of storage storehouse-adhered layer-controlled release layer unification, simplifies present framework controlled release structural manufacturing process greatly, and substrate has nontoxic, no sensitization, stores advantages such as dose is big; The substrate scope of application of the present invention is very wide to be comprised and is used for the various liquid state that percutaneous absorbs or the Western medicine preparation of semi liquid state, also can be used for Chinese medicine, with dosage forms such as alternative lead plaster agent and rubber plaster, and water preparation, tincture, extractum, esters preparation and Chinese medicine extract all can use; In addition, substrate of the present invention itself is exactly iontophoresis type electrode, during its electrical impedance 2HZ, and≤15K Ω; During 100HZ≤5K Ω; During 500KHZ≤and 1K Ω, can be made into pharmaceutical electrode, therefore substrate of the present invention is a kind of ideal drug matrices.
Further set forth characteristics of the present invention below by instantiation.
Example 1
This example is a preparation substrate.Earlier the 30g acrylamide is dissolved in the 15ml deionized water and obtains substrate solution; In the 10ml deionized water, put into the 8g gelatin, mix with the 21ml glycerol behind the maceration, 70 ± 5 ℃ of dissolvings down; With substrate solution and gelatin-glycerol solution mixing, add the 0.1gN-N methylene-bisacrylamide again, fully stir evenly and obtain treating poly-liquid; Be poured on non-woven fabrics and the compound lining material of plastics salivation film after in treating poly-liquid, adding 0.2g Ammonium persulfate. and 0.04g sodium sulfite and shakeout,, make substrate 90g and cover adherent layer, excision forming at 40 ℃ of following polymerization 5min.
Example 2
This example is a preparation substrate.
Get the 11.5g sodium hydroxide and be dissolved in the 35ml deionized water, gently sodium hydroxide solution is poured in the acrylic acid in ice is molten then, the control degree of neutralization is 65%; The 30g acrylamide is dissolved in the 18ml deionized water; To add 45ml glycerol, ethylene glycol 16ml, 0.22ml diallyl p phthalate again after above-mentioned two kinds of solution mixing, fully mix the back and add 0.5g Ammonium persulfate. and 0.1g sodium sulfite, pour on the compound lining material and shakeout, at 75 ± 5 ℃ of following polymerization 5min, make 170g substrate, cover adherent layer, excision forming gets final product.
Example 3
This example is to make plaster with Chinese medicine.
This example is except adding the mixed solution of being made up of 15ml safflower oil (Chinese medicine), 2ml tween 80 and 10ml deionized water before example 1 adds the initiator polymerization, and other process and condition are all with example 1.
Example 4
This example is to produce the transdermal adsorbent with Western medicine.Except add fluorouracil solution (it is formulated that the 1g fluorouracil adds the 12ml deionized water) and 2.6ml azone before example 2 adds the initiator polymerization, other step and condition are with example 2.
Example 5
This example is to sneak into medicine and potassium chloride prepares pharmaceutical electrode in substrate.
The 30g acrylamide is dissolved in the 25ml deionized water, add 1.25g potassium chloride, 0.5gN_N methylene diacrylamide and 21ml glycerol, add the 15ml Radix Et Rhizoma Rhei extract behind the mixing, stir and make mixed liquor, in mixed liquor, add 0.2g Ammonium persulfate. and 0.04g sodium sulfite then, be poured on by on aluminium foil and the non-woven fabric compounded conduction backing that becomes and shakeout, at 40 ℃ of following polymerization 2min, cover adherent layer at medicine face at last, excision forming gets final product.Described Radix Et Rhizoma Rhei extract is that the 10g Radix Et Rhizoma Rhei is ground into corase meal, and with alcohol reflux three times, totally 1.5 hours, three extracting solution are merged the back, and to reclaim ethanol to extracting solution proportion be till 1: 12.
Example 6
This example is with substrate of the present invention man to be exempted from the normal skin patch test.
Experiment is to be undertaken by the requirement of bureau of drug administration of Ministry of Health of the People's Republic of China " the clinical and preclinical study guideline of new drug (Western medicine) ".The substrate of experiment is the raw material (not comprising medicine) and the consumption of example 5, and preparation process and condition are also with example 5.The skin allergy experimental result sees the following form: grouping number of animals (only) anaphylaxis response strength
Meansigma methods *The sensitization rate, * %Matrix group 400 weak sensitivity response positive controls 4 6.25 100 are sensitivity response blank group 400 weak sensitivity responses extremely
*Reaction meansigma methods=(erythema forms total mark+edema and forms total points/total number of animals);
*Erythema or edema (no matter weight/animal subject number) appear in sensitization rate=skin.
The stimulation test result is as follows:
Stimulate and estimate score value<0.5; Stimulus intensity is estimated: nonirritant.

Claims (10)

1. an adhesive polymer substrate is characterized in that in the presence of cross-linking agent, polymer monomer base material, solvent, deionized water, wetting agent, additive, initiator mixed surperficial substrate with autohension, concrete preparation process comprises:
(1) the polymer monomer base material is dissolved in the deionized water, makes substrate solution;
(2) in (1) step substrate solution, add wetting agent, solvent, additive, fully stir evenly, obtain mixed liquor;
(3) cross-linking agent is joined in (2) mixed liquor in step, stir evenly, obtain treating poly-liquid;
(4) (3) step treat add initiator in the poly-liquid, shakeout through being poured on behind the mixing on the backing layer carrier, at 25-80 ℃ of following polymerase 10 .5-30min, cover adherent layer, excision forming gets final product, stromal thickness is 50 μ m-3.0mm.
2. according to the described substrate of claim 1, it is characterized in that described polymer monomer base material be selected from acrylic acid amides, sodium acrylate, the polyvinyl alcohol any, two or three mixture, its addition is the 4-40% of substrate weight.
3. according to the described substrate of claim 1, it is characterized in that described solvent comprises esters, low mass molecule alcohol class, its addition is the 4-40% of substrate weight, and described deionized water is the 12-40% of substrate weight.
4. according to the described substrate of claim 1, it is characterized in that described additive comprises Polyethylene Glycol, gelatin, alginate, hydroxypropyl cellulose, its addition is the 0-15% of substrate weight, and described wetting agent comprises propylene glycol, glycerol, and its addition is the 12-35% of substrate weight.
5. according to the described substrate of claim 1, it is characterized in that described cross-linking agent comprises the bisacrylamide class, the allyl esters, halogenation alkylene oxide hydro carbons and polyepoxy compound, described bisacrylamide class comprises the N-N methylene-bisacrylamide, methylene diacrylamide, described allyl esters comprises dially phthalate, diallyl p phthalate, diallyl oxalate, maleic acid monoene propyl ester, described halogenation alkylene oxide hydro carbons comprises epoxychloropropane, and described polyepoxy compound comprises Ethylene glycol diglycidyl ether, propylene glycol diglycidylether, its addition of glycerin diglycidyl ether is the 0.02-0.5% of polymeric substrate weight.
6. according to the described substrate of claim 1, it is characterized in that described initiator comprises the peroxide thing initiator or the redox initiator of benzoyl peroxide, persulfate-sodium sulfite, hydrogen peroxide-L ascorbic acid.Its addition is the 0.01-0.1% of base material weight.
7. in accordance with the method for claim 6, when it is characterized in that described polymeric substrate is polyvinyl alcohol, after the adding deionized water expands, make its whole dissolvings at 80-95 ℃; When using acrylic monomers, make sodium hydroxide solution with deionized water earlier, again it is joined in the acrylic acid, and control degree of neutralization 50-90%, make sodium acrylate.
8. the application of the described base material of claim 1, it is characterized in that substrate can be used for preparing the percutaneous dosing dosage form that comprises cutaneous permeable agent, the agent of percutaneous iontophoresis, system is with medicine dissolution or be blended in the substrate and obtain through polymerization, perhaps drug solution or drug suspension are spread upon stromal surface equably, cover adherent layer, leave standstill and made in two days.
9. according to the described application of claim 8, when it is characterized in that medicament mixed in substrate, can be with medicine and transdermal permeation-promoter, surfactant is mixed together with the component of substrate in preparation substrate process, after polymerization, promptly obtain required product, described transdermal permeation-promoter comprises oleic acid, oleyl alcohol, azone, sodium chloride, sodium chloride, cineole, Mentholum, its addition is the 0.5-20% of drug dose, described surfactant comprises ion-type, nonionic, neutral, its addition is the 0-20% of drug dose, and described medicine comprises water preparation, tincture, extractum esters preparation and Chinese medicine extract are at interior Western medicine and Chinese medicine.
10. according to the described application of claim 8, when it is characterized in that being applied to prepare pharmaceutical electrode, the conduction backing carrier of usefulness comprises the conduction-insulating composite material of aluminum-plastics, conductive plastics-non-woven fabrics.
CNB991030621A 1999-03-19 1999-03-19 Adhesive polymer substrate and its application Expired - Fee Related CN1149976C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB991030621A CN1149976C (en) 1999-03-19 1999-03-19 Adhesive polymer substrate and its application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB991030621A CN1149976C (en) 1999-03-19 1999-03-19 Adhesive polymer substrate and its application

Publications (2)

Publication Number Publication Date
CN1267516A true CN1267516A (en) 2000-09-27
CN1149976C CN1149976C (en) 2004-05-19

Family

ID=5271104

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB991030621A Expired - Fee Related CN1149976C (en) 1999-03-19 1999-03-19 Adhesive polymer substrate and its application

Country Status (1)

Country Link
CN (1) CN1149976C (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1329022C (en) * 2004-08-31 2007-08-01 贵州太和制药有限公司 Hydrophilic biological sticking gel pasting agent and preparation technique thereof
US7868072B2 (en) 2004-04-22 2011-01-11 Sekisui Plastics Co., Ltd. Gel adhesive compositions, method of making, and use thereof
CN109338735A (en) * 2018-11-29 2019-02-15 牛墨石墨烯应用科技有限公司 A kind of heat-insulated grid cloth of graphene fiber and preparation method thereof
CN109954329A (en) * 2017-12-25 2019-07-02 中国科学院上海硅酸盐研究所 A kind of anti-haze filtering layer material of plant fiber self-supporting graphene and its preparation method and application
CN109954479A (en) * 2017-12-25 2019-07-02 中国科学院上海硅酸盐研究所 A kind of anti-haze filtering layer of self assembly graphene and its preparation method and application

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7868072B2 (en) 2004-04-22 2011-01-11 Sekisui Plastics Co., Ltd. Gel adhesive compositions, method of making, and use thereof
CN1946826B (en) * 2004-04-22 2011-03-23 积水化成品工业株式会社 Gel adhesive composition
CN101862462B (en) * 2004-04-22 2013-04-17 积水化成品工业株式会社 Electrode
CN1329022C (en) * 2004-08-31 2007-08-01 贵州太和制药有限公司 Hydrophilic biological sticking gel pasting agent and preparation technique thereof
CN109954329A (en) * 2017-12-25 2019-07-02 中国科学院上海硅酸盐研究所 A kind of anti-haze filtering layer material of plant fiber self-supporting graphene and its preparation method and application
CN109954479A (en) * 2017-12-25 2019-07-02 中国科学院上海硅酸盐研究所 A kind of anti-haze filtering layer of self assembly graphene and its preparation method and application
CN109338735A (en) * 2018-11-29 2019-02-15 牛墨石墨烯应用科技有限公司 A kind of heat-insulated grid cloth of graphene fiber and preparation method thereof
CN109338735B (en) * 2018-11-29 2020-12-08 牛墨石墨烯应用科技有限公司 Graphene fiber heat-insulation mesh cloth and preparation method thereof

Also Published As

Publication number Publication date
CN1149976C (en) 2004-05-19

Similar Documents

Publication Publication Date Title
US4482534A (en) Nitroglycerin preparations
CN1119997C (en) Percutaneous tap preparation containing fentanyl
US4505891A (en) Medicinal adhesive sheets for heart diseases and a process for the preparation thereof
US5525356A (en) Amphoteric N-substituted acrylamide hydrogel and method
RU2401126C2 (en) Polymer adhesion matrix with carboxyl groups, forming salts for transdermal administration
JPH10182439A (en) Adhering and joining agent for skin or endermic treatment system
CN105153359A (en) Conductive hydrogel, conductive hydrogel coil and their preparation methods
US5646221A (en) Adhesive base material
EP1253913A1 (en) Patch for local and transdermal administration of active ingredients containing anionic or electron-attracting groups
CN1149976C (en) Adhesive polymer substrate and its application
CN110975004A (en) A liquid woundplast containing Notoginseng radix extract for rapidly forming film
EP0752457B1 (en) Hydrophilic adhesive base material
JPH03178663A (en) Therapeutic composite material
JPS596285B2 (en) External parts
CN105287667A (en) Traditional Chinese medicine liquid patch for treating arthritis and rheumatism
JPS6342602B2 (en)
DE876311C (en) Process for the production of self-adhesive bandages
JPS597689B2 (en) pharmaceutical formulations
JPS61126020A (en) Plaster for external use
JPS60123416A (en) Drug delivery member
JPS607966B2 (en) patch
JPS5928534B2 (en) patch
CN1291759C (en) Coblended contact glue of poly N-ethenyl pyrrolidone and polyvinyl alcohol and its use
JPH09268123A (en) Cataplasm for local anesthesia
JPS6159607B2 (en)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040519